

Estrogen Metabolism

Tara Scott, MD. FACOG, FAAFM, ABOIM

1

Webinar Technical Issues & Clinical Questions

- Please type any technical issue or clinical question into either the “Chat” or “Questions” boxes, making sure to send them to “Organizer” at any time during the webinar.
- We will be compiling your clinical questions and answering as many as we can the final 15 minutes of the webinar.

All rights reserved © 2020 Precision Analytical Inc.

2

Need more resources? Ensure you have an account!

- Contact Customer Service at 503.687.2050 or go to <https://dutchtest.com/providers/> to open your account today!

BECOME A PROVIDER TODAY!



All rights reserved © 2020 Precision Analytical Inc.

3

WHO Am I?



- Tara Scott, MD
- Board certifications in:
OB/GYN, Integrative Medicine,
and Anti-Aging, Functional
and Regenerative Medicine
- Lecture around the world
teaching doctors a functional
approach to women's health
- Medical Director of Integrative
Medicine at Summa Health in
Akron, OH

4

Objectives



Review the basics of estrogen metabolism



Define SNPs and how they affect metabolism



Discuss which SNPs affect the risk of breast cancer



Review a case and demonstrate the information the DUTCH test provides

5

Why is it so important to check estrogen metabolism?

- Is it really possible to have a randomized placebo controlled trial with hormone therapy?
- You need to consider:
 - Weight, age, oophorectomy status
 - Pharmacokinetics- what the body does to the drug
 - Pharmacodynamics- what the drug does to the body


6

Suppose I tell all my patients to drink 2 liters of water

Marathon Runner in 80 degree weather




Dialysis Patient



7


Menstrual Cycle

- Developing egg makes Estrogen-causes growth
- After its released, progesterone balances estrogen



8

What do we Know




This was our Endocrinology Bible in residency!!

9

Menstrual Cycle

- Developing egg makes Estrogen - causes growth
- After its released, progesterone balances estrogen



10




Estrogen- Functions

- Promotes growth
- Body development
- Slows bone loss
- Three main types
 - Estradiol- good for heart and bones
 - Estriol - good for skin
 - Estrone- goes to breast- sort of the bad one




13




Estrone (E1)

Predominant estrogen in **postmenopausal** women.



Estradiol (E2)

Predominant estrogen in **premenopausal** women. Most biologically active estrogen in women






Estriol (E3)

Predominant estrogen in **pregnant** women. Most abundant estrogen in urine.

Samavat & Kurzer, 2015



14

Samavat & Kurzer, 2015

Estrone (E1)


Primarily synthesized from **androstenedione** by aromatase conversion in the ovaries.
Reversibly converted into estradiol by enzyme, 17 β -hydroxysteroid dehydrogenase Type II.

Estradiol (E2)

Primarily synthesized by **developing follicle** in the ovaries.
Reversibly converted into estrone by enzyme, 17 β -hydroxysteroid dehydrogenase Type I.

Estriol (E3)

Synthesized from **estrone**, which can be converted from the hydroxylation of estradiol or 16-Hydroxyestrone.



15



I think of Estrogen
like three sisters




16

Boothby, Lisa A., et Al. "Bio identical hormone therapy: a review" in *Menopause*, 2004, vol 11, No. 3, pp.356-367

| | Estrogen Receptor- Alpha | Estrogen Receptor- Beta |
|---------------------|--------------------------|-------------------------|
| 17- Beta-estradiol | 100 | 100 |
| 17- alpha-estradiol | 58 | 11 |
| Estriol | 14 | 21 |
| Estrone | 60 | 37 |
| 4-OH-Estradiol | 13 | 7 |
| 2-OH-Estrone | 2 | 0.2 |
| Tamoxifen | 4 | 3 |
| Raloxifene | 69 | 16 |


17



Other sources of
Estrogens

18

PHASES OF DETOXIFICATION




Tara Scott, MD, FACOG, FAAF, ABOIM, CNMP

19

Healthy Estrogen Metabolism

20

Promotion of Healthy Estrogen Metabolism



Specific Phytonutrients

Specific Supplements

Specific Vitamins

Specific Diet

Healthy Intestine


Minerals

Correct Insulin Resistance

20

Estrogen Metabolism

More simplified . . .



Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

23

The “Good” Estrogens

2-HYDROXYESTROGENS:

Estrogen Metabolites

- Considerable weak with overall low hormonal potency and low binding affinity to estrogen receptors¹.
- 2-hydroxyestrogen have anti-proliferative effects in breast tissue^{1,2}.

1. Sammis et al., 2015
2. Gupta et al., 1998

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

24

Estrogen Metabolites

The “Good” Estrogens

METHOXYESTROGENS:



- Methoxyestrogens are deactivated forms of estrogen formed from methylation of catechol estrogens.
- This methylation conjugation prevents the biotransformation of hydroxyestrogens into quinone-DNA adducts (DNA damage) and the byproduct formation of reactive oxygen species.
- Methoxyestrogens also inhibits cell proliferation by inhibiting mitosis^{1,2,3}.

1. Dowling et al., 2003
2. Lakkani et al., 2003
3. Luttering et al., 1992

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

25

Estrogen Metabolites

The “Bad” Estrogens



4-HYDROXYESTROGEN QUINONE METABOLITES

- Lead to the formation of depurinating adducts¹.
- Women with or at high risk for breast cancer had high levels of adducts in their urine².
- In cellular preparations of adenocarcinoma, 4-hydroxyestradiol was 4x higher than 2-hydroxyestradiol³.

1. Cavallini et al., 1997
2. Cavallini & Rogan, 2010
3. Luster & Ricci

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

26

Estrogen Metabolites

The “Bad” Estrogens

16 α -HYDROXYESTRONE



- 16 α -Hydroxyestrone is the intermediate between estrone and estriol.
- Higher urinary concentrations of 16 α -Hydroxyestrone were associated with mammary cell proliferation in animals¹.
- 16 α -Hydroxyestrone has been found to be higher cancer breast tissue relative to normal breast tissue².
- 16 α -Hydroxyestrone is inversely proportional to 2-hydroxyestrone.
- Recent evidence has drawn into question the significance in the 16 α -Hydroxyestrone breast cancer relation^{3,4}.

1. Yang et al., 1992
2. Chang et al., 2002
3. Chu et al., 2011
4. Huang et al., 2012


Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

27

Preventing Negative Estrogen Burden



INSECTICIDES (e.g., endosulfan) has been found to inhibit the expression of CYP-1A1, resulting in reduced activity of the 2-hydroxyE pathway¹.



1. Gorman et al., 2001

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP


28

Preventing Negative Estrogen Burden

✓
RESVERATROL prevents the formation of depurinating estrogen DNA adducts in human breast cells treated with E¹.

Resveratrol inhibits peroxidase activity, reducing the formation of catechol estrogen quinones¹.

Resveratrol also increases NQO1 quinone reductase activity².



1. Cavalieri & Rogers, 2010
2. Zdzienicka et al., 2008


Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

29

Preventing Negative Estrogen Burden

✓
N-ACETYLCYSTEINE prevents electrophilic damage to DNA by inhibiting the formation of electrophilic quinones.

It has been found that the consumption of N-acetylcysteine for a 1-month period resulted in 55% reduction in urinary levels of estrogen DNA adducts¹.



1. Cavalieri & Rogers, 2010
2. Zdzienicka et al., 2008

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP


30

Preventing Negative Estrogen Burden

IODINE plays a critical role in the maintenance and functioning of mammary gland tissue.

There exists high rates of breast cancer among women with thyroid abnormalities^{1,2}.

Women with breast cancer tend to have larger thyroid volumes than controls, indicating an association between iodine deficiency and breast cancer^{1,2}.



1. Smyth et al., 1995
2. Vassilopoulou-Selzer et al., 1999

Tara Scott, MD, FACOG, FAFM, ABOIM, CNMP

31


Preventing Negative Estrogen Burden

IODINE supplementation is effective at diminishing ductal hyperplasia in rats¹.

Patients with benign breast disease that received iodine treatment experienced significant bilateral breast reduction².

Japanese communities that consume high amounts of seaweed (high [I]) have reported lower incidences of benign and malignant tissue³.

Iodine is thought to exhibit its beneficial effects by modulating estrogen metabolism^{4,5}.




1. Edwards et al., 1985
2. Grant et al., 1984
3. Com et al., 2000
4. Smith, 1993
5. Watanabe et al., 2004

Tara Scott, MD, FACOG, FAFM, ABOIM, CNMP

32

Preventing Negative Estrogen Burden

Increase
2-HydroxyE
Pathway
Activity




Tara Scott, MD, FACOG, FAAF, ABOIM, CNMP

33

Preventing Negative Estrogen Burden

- Increase **CYP 1A1**
- Increase **COMT**
- Increase **quinone reductase**
- Increase **glutathione conjugation**




Tara Scott, MD, FACOG, FAAF, ABOIM, CNMP

34

significantly decreases glucuronidase activity¹.


CALCIUM-D-GLUCARATE is a potent beta-glucuronidase inhibitor that has been shown to exert anticarcinogenic effects¹.



1. Bouhnik et al., 1990
2. Wilkerson et al., 1992

35

Estrogens & Estrogen Metabolites



PRECISION
ANALYTICAL INC.


3138 NE Rivergate Street, Suite #301C, McMinnville, OR 97128
Phone: 503/687-2050
DutchTest.com

TOTAL SCORE, FTD, FFA/COG, FFAFM, ABOIM, CNMP

Urinary Hormone Results


36

DUTCH sample report



Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

37



Genetics 101

What is DNA?



38

Genetics 101

What is a Single Nucleotide Polymorphism (SNP)?

A SNP (pronounced "snip") is a DNA sequence variation that occurs when a single nucleotide (A, T, C, or G) in the genome sequence is modified.


SNPs do not necessarily cause disease, but they can help determine the likelihood that someone will develop a particular illness.



39

Not all SNPs
are significant


It depends
on where it
is located.



40

Genetics 101

Effects of SNPs
on protein
shape



41

Genetics 101

Some SNPs change
the meaning but
not the function

Dr. Jay Scott



Dr. Joy Scott



42

Genetics 101

Some SNPs are of
no consequence

Are you coming **too**? Are you **two** coming?



43

Genetics 101

Some SNPs just
denote ethnicity

Color
Personalize



Colour
Personalise



44

Genetics 101

Some SNPs
totally change
the meaning

Cut



Cat




45

Genetics 101

Genetic Inheritance

- Heterozygous - one variation
- Homozygous - two variations

Tara Scott, MD, FACOG, FAAFM, ABOIM



46

Genetic Polymorphisms

MTHFR C677T

Methylenetetrahydrofolate

- MTHFR is responsible for reducing folate into its active form.
- MTHFR C677T involves a base change from cytosine to thymine at base 677.
- MTHFR C677T is the most common SNP in the folate cycle^{1,2}.

1. Hiraoka & Kagawa, 2017
2. Miller 2003

47

Genetic Polymorphisms

MTHFR C677T


Treatment of MTHFR C677T

MTHFR C677T can be enhanced by treatment with folate and/or vitamin B12.

- E.g., In a study that assessed individuals with high dietary folate intake (>225 mcg/day), serum folate levels were significantly lower in individuals with 677TT than those with 677CC¹.
- Authors recommended that individuals homozygous for 677TT consume approximately **1.4 times more folate** to reach levels seen in individuals with 677CC or 677TC genotypes¹.

1. Nishio et al., 2008

48



49

Genetic Polymorphisms

COMT

Catechol-O-Methyl Transferase (COMT)

COMT is responsible for the metabolism of monoamines and catechol estrogens.

COMT V158M involves a base change from valine to methionine at base pair 158.

COMT V158M results in reduced COMT activity.

Reduced COMT activity is associated with **higher dopamine and norepinephrine levels**¹, **lower pain tolerance**², and **catechol estrogen accumulation (DNA damage)**³


E.g., Individuals with homozygous 158MM genotype administered significantly more morphine post-surgery².

1. Kotyuk et al., 2015
2. Tan et al., 2016
3. Ashton et al., 2006

50

Genetic Polymorphisms

COMT




1. Kotlyak et al., 2015
2. Tan et al., 2016
3. Ashton et al., 2006

51

CYP 19A1


Converts Androgens (androstenedione and testosterone) into estrogens (estradiol and estrone)
If this is a fast version, it will make estrogen dominance worse



52

CYP 1B1 Metabolizes estrogen in 4 OH estrogens

If this is FAST, will increase the risk of estrogen dominance, especially if coupled with a slow COMT




53



54

EPIGENETICS-Agouti Mice Experiment



55

Case – Part 1

56



Emma was a new patient, and her main complaint was severe PMS and anxiety. She has a lot of stress with 3 young children. The oldest was born prematurely at 28 weeks and has mild cerebral palsy.

Her main complaints were anxiety, poor sleep, and stress.

Medications: Vitamin D
Multivitamin

Family history: Thyroid disease- mother
Celiac disease- sister

Tara Scott, MD, FACOG, FGAAPM, ABOIM, CNMP

56



Case – Part 1

57

- CORTISOL - PM: 6.8
- FERRITIN, SERUM: 40
- PROGESTERONE: 13.0
- TRIIODOTHYRONINE, FREE, SERUM: 2.8
- **DHEA-SULFATE: 361.1 High**
- **VITAMIN D, 25-HYDROXY: 21.3 Low**
- TSH: 2.080
- T4, FREE(DIRECT): 1.00
- REVERSE T3, SERUM: 13.8
- PREGNENOLONE, MS: 135
- **DIHYDROTESTOSTERONE: 3.2 Low**
- IRON BIND.CAP.(TIBC): 355
- UIBC: 272
- IRON, SERUM: 83
- IRON SATURATION: 23
- ENDOMYSIAL ANTIBODY IGA: NEGATIVE
- T-TRANSGLUTAMINASE (TTG) IGA: <2
- T-TRANSGLUTAMINASE (TTG) IGG: <2
- IMMUNOGLOBULIN A, QN, SERUM: 290

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

57

Saliva Hormone Results 2015

Salivary Hormone Results

Estradiol ♦ pmol/L

7.0

| | Reference Range |
|------------|-----------------|
| Follicular | 2.8-8.8 pmol/L |
| Peak * | 4.5-19.1 pmol/L |
| Luteal | 2.8-8.2 pmol/L |
| Menopausal | 3.7-9.4 pmol/L |
| Male | 3.1-7.4 pmol/L |

* Peak = Days 11 and 12

Testosterone ♦ pmol/L

<30

| | Reference Range |
|---------------|-----------------|
| Premenopausal | 34-148 pmol/L |
| Menopausal | 34-148 pmol/L |
| Male | 110-513 pmol/L |

Estrone pmol/L

14.0

| | Reference Range |
|------------|-----------------|
| Menopausal | 4.7-18.9 pmol/L |

Progesterone ♦ pmol/L

397

| | Reference Range |
|------------|-----------------|
| Follicular | 120-593 pmol/L |
| Peak * | 328-1385 pmol/L |
| Luteal | 145-797 pmol/L |
| Menopausal | 163-669 pmol/L |
| Male | 141-529 pmol/L |

* Peak = Days 18 and 20

Estriol pmol/L

80

| | Reference Range |
|------------|-----------------|
| Menopausal | <= 133 pmol/L |

P/E2 Ratio

57


| | Reference Range |
|------------|-----------------|
| Follicular | 23-159 |
| Luteal | 25-141 |
| Menopausal | 33-116 |

Genova Diagnostics. Genova Diagnostics is not involved in the teachings, opinions, or the diagnostic and treatment modalities discussed in this program.

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

58

Saliva Hormone Results 2015



Genova Diagnostics. Genova Diagnostics is not involved in the teachings, opinions, or the diagnostic and treatment modalities discussed in this program.

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

59

Treatment Plan

Pt was treated with cyclic oral Progesterone 100mg days 14 until the next cycle begins

Vitamin D was replaced with D3 drops

Adaptogens were suggested for high cortisol

Patient information - Permission for use granted by T. Scott, MD, FACOG, FAAFM, ABOIM, CNMP
Laboratory Results - Adopted from Genova Diagnostics. Permission for use granted by A.L. Pease-Brower, PhD, DAB(MJ), Lab Director at Genova Diagnostics. Genova Diagnostics is not involved in the teachings, opinions, or the diagnostic and treatment modalities discussed in this program.

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

60

Genomics Results- 2016

| COMT | Val158Met AG | Intermediate COMT Activity | Val158Met |
|-----------------|---------------|--|---|
| CYP1A2 | *1F/*1F | Normal Metabolizer - Higher Inducibility | *1C, *1D, *1E, *1F, *1J, *1K, *1L, *1V, *1W |
| CYP2B6 | *1/*5 | Unknown Phenotype | *2, *3, *5, *6, *9, *18, *28 |
| CYP2C19 | *1/*1 | Normal Metabolizer | *2, *3, *4, *4B, *5, *6, *7, *8, *9, *10, *17 |
| CYP2C9 | *1/*2 | Intermediate Metabolizer | *2, *3, *5, *6, *8, *11, *27 |
| CYP2D6 | *4/*4 | Poor Metabolizer | *2, *3, *4, *4M, *6, *7, *8, *9, *10, *11, *12, *14A, *14B, *17, *29, *35, *41, *56A, *56B, *5 (gene deletion), XN (gene duplication) |
| CYP3A4 | *1/*1 | Normal Metabolizer | *2, *3, *12, *17, *22 |
| CYP3A5 | *3/*3 | Poor Metabolizer | *1D, *3, *3C, *6, *7 |
| DRD2 | -241A>G T/T | Homozygous for rs1799978 T Allele | -241A>G, rs2283265 |
| DRD2 | rs2283265 C/C | Homozygous for rs2283265 C allele | -241A>G, rs2283265 |
| Factor II | 20210G>A GG | Normal Thrombosis Risk | 20210G>A |
| Factor V Leiden | 1691G>A GG | Normal Thrombosis Risk | 1691G>A |
| MTHFR | 1298A>C AA | Normal MTHFR Activity | 1298A>C |
| MTHFR | 677C>T CT | Reduced MTHFR Activity | 677C>T |

Tara Scott, MD, FACOG, FAAFM, ABOIM, CNMP

61

CASE FOLLOW-UP

PT presented back to review serum labs- done mid luteal

| Lab | Results | Normal Range |
|--------------------|---------|--------------|
| Estrone: | 86 | 54-179 |
| Estradiol: | 122 | 43-211 |
| DHEAS | 312 H | 57-297 |
| Total Testosterone | 20 | 8-48 |
| Free Testosterone | 2.6 | 0.0-4.2 |
| Progesterone | 11.0 | 1.8- 23.9 |

62

CASE FOLLOW-UP



Pt had previously been seen for stool results



Digestive Issues




Poor Diversity




Decided to change to Progesterone troche for better absorption – 75mg

63

CASE Follow Up- DUTCH TESTING



64



67

Organic Acids

| Category | Test | Result | Units | Normal Range |
|--|----------------------|--------------|-------|-----------------|
| Nutritional Organic Acids | | | | |
| Vitamin B12 Marker (may be deficient if high) - (Urine) | | | | |
| | Methylmalonate (MMA) | Above range | 2.4 | ug/mg 0 - 2.2 |
| Vitamin B6 Markers (may be deficient if high) - (Urine) | | | | |
| | Xanthurenate | Within range | 0.4 | ug/mg 0 - 1.4 |
| | Kynurenate | Within range | 2.4 | ug/mg 0 - 7.3 |
| Glutathione Marker (may be deficient if low or high) - (Urine) | | | | |
| | Pyroglutamate | Within range | 45.7 | ug/mg 32 - 60 |
| Neurotransmitter Metabolites | | | | |
| Dopamine Metabolite - (Urine) | | | | |
| | Homovanillate (HVA) | Within range | 6.4 | ug/mg 4 - 13 |
| Norepinephrine/Epinephrine Metabolite - (Urine) | | | | |
| | Vanilmandelate (VMA) | Within range | 4.9 | ug/mg 2.4 - 6.4 |
| Melatonin (*measured as 6-OH-Melatonin-Sulfate) - (Urine) | | | | |
| | Melatonin* (Waking) | Within range | 26.1 | ng/mg 10 - 85 |
| Oxidative Stress / DNA Damage, measured as 8-Hydroxy-2-deoxyguanosine (8-OHdG) - (Urine) | | | | |
| | 8-OHdG (Waking) | Within range | 1.3 | ng/mg 0 - 5.2 |

68


Treatment options



HOW WOULD YOU CHANGE
PROGESTERONE DOSE?



HOW WOULD YOU
SUPPORT METHYLATION?



WHAT WOULD YOU GIVE
FOR ADRENAL SUPPORT?

69

Conclusions

Estrogen metabolism
should be monitored for
any premenopausal
patient with risk factors

Consider genetic testing
for patients with
symptoms of poor
methylation

Epigenetic modulation of
estrogen metabolism is
effective!

DUTCH test is a
comprehensive test to
look at estrogen
metabolism and
methylation

70

71



The medical community's new choice
for hormone and wellness medicine.



@tdscottmd





RevitalizeMed

RevitalizeMed




71

72

...and that concludes our talk

Thank you for listening.

info@dutchtest.com



Like Us, Follow Us, or Leave a Review!


<https://www.facebook.com/dutchtest>

<https://twitter.com/DutchTestLab>

<https://www.linkedin.com/company/10883377>

<https://www.instagram.com/dutchtest/>

<https://www.youtube.com/channel/UCauTDzKu4VS74PMiYgda-PQ>



All rights reserved © 2020 Precision Analytical Inc.

72